GSK plc announced that on April 24, 2024, the US FDA accepted its application for an expanded use of Jemperli (dostarlimab), allowing treatment for all adults with advanced endometrial cancer, with a decision expected by August 23, 2024, based on significant clinical trial data showing improved survival rates.